Othman Al-Sawaf, Sandra Robrecht, Matthew S Davids, Mary Ann Anderson, Romain Guieze, Valeria Buccheri, Celso Arrais-Rodrigues, Francesc Bosch Albareda, Ruth Clifford, Michael Doubek, Krzysztof Jamroziak, Arnon Kater, Mattias Mattsson, Carsten Niemann, Miguel Pavlovsky, Lydia Scarfò, Renata Walewska, Peng Liu, Ki-Seong Eom, Karl Kreuzer, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Kenneth Wu, Marcus Lefebure, Wei Ding, Remus Vezan, Barbara Eichhorst. "A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)." Blood, 2025. doi:10.1182/blood-2025-2137